BeStock  
Stocks › Biotechnology › DFTX

Definium Therapeutics DFTX

US equityMarket cap rank #2233Biotechnology
$28.34 −$1.14 (-3.87%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $28.05 -1.02%
Open$29.14
Prev close$29.48
Day range$28.18 – $29.51
Volume3.24M
Market cap$3.88B
P/E (TTM)–
Dividend yield–

Earnings

Average move on report day±2.0%last 4 reports
Closed higher1 of 425% of the time
Best reaction+0.9%
Worst reaction-5.0%

Stock move on the day after each report

+0.9%2025/Q4-5.0%2026/Q1+0.0%2026/Q2-2.1%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q39 Nov 2026After Market±12.8%-2.12%Within range
2026/Q26 Aug 2026After Market±23.4%+0.00%Within range
2026/Q17 May 2026After Market±10.0%-4.96%Within range
2025/Q426 Feb 2026After Market±12.3%+0.93%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Latest reported quarter: Q3, ended Sep 2026

Revenue$0.00
Operating profit-$72.28M-58.3% YoY
Net profit-$50.96M+24.2% YoY
Diluted EPS-$0.46+41.0% YoY
Free cash flow-$52.98M-79.2% YoY
Operating cash flow-$52.98M

Revenue, last 8 quarters

$0.0Dec '24$0.0Mar '25$0.0Jun '25$0.0Sep '25$0.0Dec '25$0.0Mar '26$0.0Jun '26$0.0Sep '26

Net profit, last 8 quarters

$-34.7MDec '24$-23.3MMar '25$-42.7MJun '25$-67.3MSep '25$-50.4MDec '25$-77.1MMar '26$-159.0MJun '26$-51.0MSep '26

Profitability & balance sheet

Return on equity-61.4%
Return on assets-51.5%
Return on invested capital-60.1%
Current ratio15.53
Liabilities / assets9.9%
Cash & investments$1.05B
Total debt$36.66M
Net cash (debt)$1.01B

Discussion

No comments yet — be the first to weigh in on DFTX.

Sign in to join the discussion.

Scroll to Top